Novel Drug Beats Avonex for MS Efficacy; Safety Still a Worry
BOSTON -- Daclizumab HYP cut relapse rates and disability progression in multiple sclerosis patients more effectively than interferon beta-1a (Avonex) in a phase III trial, but liver toxicity with the IL-2 inhibitor reared its head again.
Sep 12, 2014